The FDA approved Jideytro (zidesamtinib) on July 22, 2026, for previously treated ROS1-positive non-small cell lung cancer. Here is who qualifies and what the ARROS-1 trial showed.
FDA Just Approved a New Targeted Lung Cancer Drug: Who Qualifies for Jideytro Treatment
by | Jul 24, 2026 | Uncategorized | 0 comments
Recent Comments